High-performance liquid chromatographic-tandem mass spectrometric method for the determination of clemastine in human plasma. 2005

Viola Horváth, and Antal Tolokán, and Andrea Egresi, and Tímea Pap, and George Horvai, and Katalin Balogh-Nemes, and Imre Klebovich
Research Group of Technical Analytical Chemistry, Hungarian Academy of Sciences-Budapest University of Technology and Economics, Gellért tér 4., Budapest H-1111, Hungary. vhorvath@mail.bme.hu

A highly sensitive high-performance liquid chromatographic-tandem mass spectrometric method (HPLC-MS-MS) has been developed to quantitate clemastine in human plasma for the purpose of pharmacokinetic studies. Sample preparation was carried out by liquid-liquid extraction using deuterated clemastine as an internal standard. Chromatographic separation used a C18 reversed phase polymer column giving an extremely fast total run time of 2 min. The method was validated and used for the bioequivalence study of clemastine tablets in healthy male volunteers (n=28). The lower limit of detection proved to be 0.01 ng/ml for clemastine.

UI MeSH Term Description Entries
D008297 Male Males
D012015 Reference Standards A basis of value established for the measure of quantity, weight, extent or quality, e.g. weight standards, standard solutions, methods, techniques, and procedures used in diagnosis and therapy. Standard Preparations,Standards, Reference,Preparations, Standard,Standardization,Standards,Preparation, Standard,Reference Standard,Standard Preparation,Standard, Reference
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D002974 Clemastine A histamine H1 antagonist used as the hydrogen fumarate in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. Meclastine,Mecloprodin,2-(2-(1-(4-Chlorophenyl)-1-phenylethoxy)ethyl)-1-methylpyrrolidine,Clemastine Fumarate,HS-592,Tavegyl,Tavist,HS 592,HS592
D003903 Deuterium The stable isotope of hydrogen. It has one neutron and one proton in the nucleus. Deuterons,Hydrogen-2,Hydrogen 2
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs
D006634 Histamine H1 Antagonists Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. Antihistamines, Classical,Antihistaminics, Classical,Antihistaminics, H1,Histamine H1 Antagonist,Histamine H1 Receptor Antagonist,Histamine H1 Receptor Antagonists,Histamine H1 Receptor Blockaders,Antagonists, Histamine H1,Antagonists, Histamine H1 Receptor,Antihistamines, Sedating,Blockaders, Histamine H1 Receptor,First Generation H1 Antagonists,H1 Receptor Blockaders,Histamine H1 Blockers,Receptor Blockaders, H1,Antagonist, Histamine H1,Classical Antihistamines,Classical Antihistaminics,H1 Antagonist, Histamine,H1 Antagonists, Histamine,H1 Antihistaminics,Sedating Antihistamines
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013810 Therapeutic Equivalency The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease. Bioequivalence,Clinical Equivalency,Equivalency, Therapeutic,Generic Equivalency,Clinical Equivalencies,Equivalencies, Clinical,Equivalencies, Therapeutic,Equivalency, Clinical,Therapeutic Equivalencies,Bioequivalences,Equivalencies, Generic,Equivalency, Generic,Generic Equivalencies
D015203 Reproducibility of Results The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results. Reliability and Validity,Reliability of Result,Reproducibility Of Result,Reproducibility of Finding,Validity of Result,Validity of Results,Face Validity,Reliability (Epidemiology),Reliability of Results,Reproducibility of Findings,Test-Retest Reliability,Validity (Epidemiology),Finding Reproducibilities,Finding Reproducibility,Of Result, Reproducibility,Of Results, Reproducibility,Reliabilities, Test-Retest,Reliability, Test-Retest,Result Reliabilities,Result Reliability,Result Validities,Result Validity,Result, Reproducibility Of,Results, Reproducibility Of,Test Retest Reliability,Validity and Reliability,Validity, Face

Related Publications

Viola Horváth, and Antal Tolokán, and Andrea Egresi, and Tímea Pap, and George Horvai, and Katalin Balogh-Nemes, and Imre Klebovich
September 1997, Journal of chromatography. B, Biomedical sciences and applications,
Viola Horváth, and Antal Tolokán, and Andrea Egresi, and Tímea Pap, and George Horvai, and Katalin Balogh-Nemes, and Imre Klebovich
April 2001, Journal of chromatography. B, Biomedical sciences and applications,
Viola Horváth, and Antal Tolokán, and Andrea Egresi, and Tímea Pap, and George Horvai, and Katalin Balogh-Nemes, and Imre Klebovich
March 1989, Biomedical & environmental mass spectrometry,
Viola Horváth, and Antal Tolokán, and Andrea Egresi, and Tímea Pap, and George Horvai, and Katalin Balogh-Nemes, and Imre Klebovich
November 2006, Biomedical chromatography : BMC,
Viola Horváth, and Antal Tolokán, and Andrea Egresi, and Tímea Pap, and George Horvai, and Katalin Balogh-Nemes, and Imre Klebovich
May 2007, Biomedical chromatography : BMC,
Viola Horváth, and Antal Tolokán, and Andrea Egresi, and Tímea Pap, and George Horvai, and Katalin Balogh-Nemes, and Imre Klebovich
January 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
Viola Horváth, and Antal Tolokán, and Andrea Egresi, and Tímea Pap, and George Horvai, and Katalin Balogh-Nemes, and Imre Klebovich
January 2007, Biomedical chromatography : BMC,
Viola Horváth, and Antal Tolokán, and Andrea Egresi, and Tímea Pap, and George Horvai, and Katalin Balogh-Nemes, and Imre Klebovich
September 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
Viola Horváth, and Antal Tolokán, and Andrea Egresi, and Tímea Pap, and George Horvai, and Katalin Balogh-Nemes, and Imre Klebovich
December 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
Viola Horváth, and Antal Tolokán, and Andrea Egresi, and Tímea Pap, and George Horvai, and Katalin Balogh-Nemes, and Imre Klebovich
January 2006, Rapid communications in mass spectrometry : RCM,
Copied contents to your clipboard!